Patents by Inventor Thomas J. Baiga

Thomas J. Baiga has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200190019
    Abstract: Provided herein are compounds and compositions useful in increasing PPAR? activity. The compounds and compositions provided herein are useful for the treatment of PPAR? related diseases (e.g., muscular diseases, vascular disease, demyelinating disease, and metabolic diseases).
    Type: Application
    Filed: December 16, 2019
    Publication date: June 18, 2020
    Applicants: Salk Institute for Biological Studies, Mitobridge, Inc.
    Inventors: Ronald M. Evans, Michael Downes, Thomas J. Baiga, Joseph P. Noel, Emi Kanakubo Embler, Weiwei Fan, John F.W. Keana, Mark G. Bock, Authur F. Kluge, Mike A. Patane
  • Publication number: 20200123113
    Abstract: Novel compounds having a formula embodiments of a method of making the same, and of a composition comprising them are disclosed herein. Also disclosed are embodiments of a method of treating or preventing a metabolic disorder in a subject, comprising administering to a subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and treating or preventing a metabolic disorder in the subject. Additionally disclosed are embodiments of a method of treating or preventing inflammation in an intestinal region of a subject, comprising administering to the subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and thereby treating or preventing inflammation in the intestinal region of the subject.
    Type: Application
    Filed: September 10, 2019
    Publication date: April 23, 2020
    Applicants: Salk Institute for Biological Studies, The University of Sydney
    Inventors: Ronald M. Evans, Michael Downes, Annette Atkins, Sungsoon Fang, Jae Myoung Suh, Thomas J. Baiga, Ruth T. Yu, John F.W. Keana, Christopher Liddle
  • Patent number: 10550071
    Abstract: Provided herein are compounds and compositions useful in increasing PPAR? activity. The compounds and compositions provided herein are useful for the treatment of PPAR? related diseases (e.g., muscular diseases, vascular disease, demyelinating disease, and metabolic diseases).
    Type: Grant
    Filed: February 15, 2018
    Date of Patent: February 4, 2020
    Assignees: Salk Institute for Biological Studies, Mitobridge, Inc.
    Inventors: Ronald M. Evans, Michael Downes, Thomas J. Baiga, Joseph P. Noel, Emi Kanakubo Embler, Weiwei Fan, John F. W. Keana, Mark G. Bock, Arthur F. Kluge, Mike A. Patane
  • Patent number: 10450277
    Abstract: Novel compounds having a formula embodiments of a method of making the same, and of a composition comprising them are disclosed herein. Also disclosed are embodiments of a method of treating or preventing a metabolic disorder in a subject, comprising administering to a subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and treating or preventing a metabolic disorder in the subject. Additionally disclosed are embodiments of a method of treating or preventing inflammation in an intestinal region of a subject, comprising administering to the subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and thereby treating or preventing inflammation in the intestinal region of the subject.
    Type: Grant
    Filed: November 27, 2018
    Date of Patent: October 22, 2019
    Assignees: The Salk Institute for Biological Studies, University of Sydney
    Inventors: Ronald M. Evans, Michael Downes, Annette Atkins, Sungsoon Fang, Jae Myoung Suh, Thomas J. Baiga, Ruth T. Yu, John F. W. Keana, Christopher Liddle
  • Patent number: 10301268
    Abstract: Novel compounds having a formula embodiments of a method of making the same, and of a composition comprising them are disclosed herein. Also disclosed are embodiments of a method of treating or preventing a metabolic disorder in a subject, comprising administering to a subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and treating or preventing a metabolic disorder in the subject. Additionally disclosed are embodiments of a method of treating or preventing inflammation in an intestinal region of a subject, comprising administering to the subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and thereby treating or preventing inflammation in the intestinal region of the subject.
    Type: Grant
    Filed: September 12, 2016
    Date of Patent: May 28, 2019
    Assignees: The Salk Institute for Biological Studies, University of Sydney
    Inventors: Ronald M. Evans, Michael Downes, Annette Atkins, Sungsoon Fang, Jae Myoung Suh, Thomas J. Baiga, Ruth T. Yu, John F. W. Keana, Christopher Liddle
  • Publication number: 20190084939
    Abstract: Novel compounds having a formula embodiments of a method of making the same, and of a composition comprising them are disclosed herein. Also disclosed are embodiments of a method of treating or preventing a metabolic disorder in a subject, comprising administering to a subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and treating or preventing a metabolic disorder in the subject. Additionally disclosed are embodiments of a method of treating or preventing inflammation in an intestinal region of a subject, comprising administering to the subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and thereby treating or preventing inflammation in the intestinal region of the subject.
    Type: Application
    Filed: November 27, 2018
    Publication date: March 21, 2019
    Applicants: Salk Institute for Biological Studies, The University of Sydney
    Inventors: Ronald M. Evans, Michael Downes, Annette Atkins, Sungsoon Fang, Jae Myoung Suh, Thomas J. Baiga, Ruth T. Yu, John F.W. Keana, Christopher Liddle
  • Patent number: 10077268
    Abstract: Novel FXR agonists are disclosed, embodiments of a method of making the same, and of a composition comprising them are disclosed herein. Also disclosed are embodiments of a method of treating or preventing a metabolic disorder in a subject, comprising administering to a subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and treating or preventing a metabolic disorder in the subject. Additionally disclosed are embodiments of a method of treating or preventing inflammation in an intestinal region of a subject, comprising administering to the subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and thereby treating or preventing inflammation in the intestinal region of the subject.
    Type: Grant
    Filed: September 12, 2016
    Date of Patent: September 18, 2018
    Assignee: Salk Institute for Biological Studies
    Inventors: Ronald M. Evans, Michael Downes, Thomas J. Baiga, John F.W. Keana, Christopher Liddle
  • Publication number: 20180170857
    Abstract: Provided herein are compounds and compositions useful in increasing PPAR? activity. The compounds and compositions provided herein are useful for the treatment of PPAR? related diseases (e.g., muscular diseases, vascular disease, demyelinating disease, and metabolic diseases).
    Type: Application
    Filed: February 15, 2018
    Publication date: June 21, 2018
    Applicants: Salk Institute for Biological Studies, Mitobridge, Inc.
    Inventors: Ronald M. Evans, Michael Downes, Thomas J. Baiga, Joseph P. Noel, Emi Kanakubo Embler, Weiwei Fan, John F.W. Keana, Mark G. Bock, Authur F. Kluge, Mike A. Patane
  • Patent number: 9938234
    Abstract: Provided herein are compounds and compositions useful in increasing PPAR? activity. The compounds and compositions provided herein are useful for the treatment of PPAR? related diseases (e.g., muscular diseases, vascular disease, demyelinating disease, and metabolic diseases).
    Type: Grant
    Filed: October 2, 2015
    Date of Patent: April 10, 2018
    Assignees: Salk Institute for Biological Studies, Mitobridge, Inc.
    Inventors: Ronald M. Evans, Michael Downes, Thomas J. Baiga, Joseph P. Noel, Emi Kanakubo Embler, Weiwei Fan, John F. W. Keana, Mark G. Bock, Arthur F. Kluge, Mike A. Patane
  • Publication number: 20170066724
    Abstract: Novel compounds having a formula embodiments of a method of making the same, and of a composition comprising them are disclosed herein. Also disclosed are embodiments of a method of treating or preventing a metabolic disorder in a subject, comprising administering to a subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and treating or preventing a metabolic disorder in the subject. Additionally disclosed are embodiments of a method of treating or preventing inflammation in an intestinal region of a subject, comprising administering to the subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and thereby treating or preventing inflammation in the intestinal region of the subject.
    Type: Application
    Filed: September 12, 2016
    Publication date: March 9, 2017
    Applicants: Salk Institute for Biological Studies, The University of Sydney
    Inventors: Ronald M. Evans, Michael Downes, Annette Atkins, Sungsoon Fang, Jae Myoung Suh, Thomas J. Baiga, Ruth T. Yu, John F.W. Keana, Christopher Liddle
  • Publication number: 20160376279
    Abstract: Novel FXR agonists are disclosed, embodiments of a method of making the same, and of a composition comprising them are disclosed herein. Also disclosed are embodiments of a method of treating or preventing a metabolic disorder in a subject, comprising administering to a subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and treating or preventing a metabolic disorder in the subject. Additionally disclosed are embodiments of a method of treating or preventing inflammation in an intestinal region of a subject, comprising administering to the subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and thereby treating or preventing inflammation in the intestinal region of the subject.
    Type: Application
    Filed: September 12, 2016
    Publication date: December 29, 2016
    Applicants: Salk Institute for Biological Studies, The University of Sydney
    Inventors: Ronald M. Evans, Michael Downes, Thomas J. Baiga, John F.W. Keana, Christopher Liddle
  • Publication number: 20160023991
    Abstract: Provided herein are compounds and compositions useful in increasing PPAR? activity. The compounds and compositions provided herein are useful for the treatment of PPAR? related diseases (e.g., muscular diseases, vascular disease, demyelinating disease, and metabolic diseases).
    Type: Application
    Filed: October 2, 2015
    Publication date: January 28, 2016
    Applicants: Salk Institute for Biological Studies, Mitobridge, Inc.
    Inventors: Ronald M. Evans, Michael Downes, Thomas J. Baiga, Joseph P. Noel, Emi Kanakubo Embler, Weiwei Fan, John F.W. Keana, Mark G. Bock, Arthur F. Kluge, Mike A. Patane
  • Patent number: 8865930
    Abstract: Disclosed herein is a method for synthesizing terpenoid compounds, as well as compositions comprising terpenoids and methods for their use. In one aspect the process is represented by the scheme wherein G is X is and R1, R2 and R3 independently are selected from H, acyl, lower alkyl and aralkyl; and Y is —O—, —S— or —NH—, and R4 is selected from H, acyl, lower alkyl and aralkyl.
    Type: Grant
    Filed: August 10, 2009
    Date of Patent: October 21, 2014
    Assignee: Salk Institute for Biological Studies
    Inventors: Joseph P. Noel, Justin Ramsey, Thomas J. Baiga
  • Patent number: 8653080
    Abstract: The disclosure provides methods and compositions useful for screening inhibitors of aggregation mediated proteotoxicity. The disclosure provides transgenic animals and cell useful for such screening. Also provided are compounds useful for inhibiting aggregation mediated proteotoxicity in a subject.
    Type: Grant
    Filed: January 14, 2010
    Date of Patent: February 18, 2014
    Assignee: Salk Institute for Biological Studies
    Inventors: Andrew Dillin, Thomas J. Baiga, Erik Kapernick, Joseph P. Noel
  • Publication number: 20110152563
    Abstract: Disclosed herein is a method for synthesizing terpenoid compounds, as well as compositions comprising terpenoids and methods for their use. In one aspect the process is represented by the scheme wherein G is X is and R1, R2 and R3 independently are selected from H, acyl, lower alkyl and aralkyl; and Y is —O—, —S— or —NH—, and R4 is selected from H, acyl, lower alkyl and aralkyl.
    Type: Application
    Filed: August 10, 2009
    Publication date: June 23, 2011
    Inventors: Joseph P. Noel, Justin A. Ramsey, Thomas J. Baiga
  • Publication number: 20100292232
    Abstract: Disclosed herein are antiviral agents, in particular non-nucleoside reverse transcriptase inhibitors (NNRTIs) of the formula Also disclosed are methods of making the NNRTIs, as well as compositions that include such NNRTIs and methods of their use for treating viral infections, in particular retroviral infections, such as HIV infection.
    Type: Application
    Filed: November 5, 2008
    Publication date: November 18, 2010
    Inventors: Daniel Elleder, John A.T. Young, Thomas J. Baiga, Joseph P. Noel
  • Publication number: 20100263062
    Abstract: The disclosure provides methods and compositions useful for screening inhibitors of aggregation mediated proteotoxicity. The disclosure provides transgenic animals and cell useful for such screening. Also provided are compounds useful for inhibiting aggregation mediated proteotoxicity in a subject.
    Type: Application
    Filed: January 14, 2010
    Publication date: October 14, 2010
    Applicant: THE SALK INSTITUTE FOR BIOLOGICAL STUDIES
    Inventors: Andrew Dillin, Thomas J. Baiga, Erik Kapernick, Joseph P. Noel
  • Publication number: 20030134432
    Abstract: A system for producing a library of oligomer comprising at least two monomers in a positionally determined array comprise a plurality of synthesis supports, a first plurality of support carriers wherein each carrier has a uniform array of distinct support holding positions for the synthesis supports; means for contacting each array of synthesis supports with a different monomer to provide a first chemical transformation of the synthesis supports; a second plurality of support carriers wherein each carrier has a uniform array of distinct support holding positions for receiving the chemically transformed synthesis supports contained in the first plurality of support carriers; transfer apparatus for transferring a selected row or column of synthesis supports from each of the first plurality of carriers to each of the second plurality of carriers to enable the supports in the second to undergo at least a second chemical transformation; and whereby each support position in each carrier identifies the chemical comp
    Type: Application
    Filed: October 29, 2002
    Publication date: July 17, 2003
    Applicant: Ontogen Corporation
    Inventors: Romaine R. Maiefski, John F. Cargill, Thomas J. Baiga
  • Patent number: 6528324
    Abstract: A system for producing a library of oligomer comprising at least two monomers in a positionally determined array comprise a plurality of synthesis supports, a first plurality of support carriers wherein each carrier has a uniform array of distinct support holding positions for the synthesis supports; means for contacting each array of synthesis supports with a different monomer to provide a first chemical transformation of the synthesis supports; a second plurality of support carriers wherein each carrier has a uniform array of distinct support holding positions for receiving the chemically transformed synthesis supports contained in the first plurality of support carriers; transfer apparatus for transferring a selected row or column of synthesis supports from each of the first plurality of carriers to each of the second plurality of carriers to enable the supports in the second to undergo at least a second chemical transformation; and whereby each support position in each carrier identifies the chemical comp
    Type: Grant
    Filed: February 8, 2000
    Date of Patent: March 4, 2003
    Assignee: Ontogen Corporation
    Inventors: Romaine R. Maiefski, Edmund J. Moran, Thomas J. Baiga